(Bloomberg) -- Drugmaker Grifols SA and US short seller Gotham ... Schools Wrecked by Fires ‘Chronos-PD’ is looking for biological signals that could indicate increased chance of developing ...

Spanish pharma Grifols is leveraging its massive collection of plasma samples to look for early biomarkers of Parkinson’s disease (PD) thanks to a $21 million grant from the Michael J.

Shares in Spanish pharma group Grifols have plummeted after UK-based hedge fund Gotham City Research issued a report claiming it has fraudulently manipulated its financial reporting by not ...

Grifols offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion, in addition to clinical diagnostic technologies. It provides high-quality biological ...

Grifols has received a $21 million grant from The Michael J. Fox Foundation to fund a pioneering study aimed at identifying ...

Private equity company Brookfield has reportedly moved closer to taking control of Grifols, after months of disruption at the Spanish pharma company. A report in Spanish newspaper El Confidencial ...

Grifols, a global healthcare company and leading producer of plasma-derived medicines, today announced it has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF ...

ADMA Biologics, which competes with Takeda TAK and Grifols GRFS in the market of plasma-derived products in the United States ...

The Biologics License Application (BLA ... ensuring timely and targeted treatment. As a member of the Grifols Group, Biotest is committed to playing a leading role in expanding access to this ...